Pharmacy

Your Article Summary

See Latest Articles

Study shows GSK's novel diabetes treatment Syncria (albiglutide) improves glucose control and reduces weight
GlaxoSmithKline, 06/09/09

New Phase II data presented at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria significantly reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly dosing. Reducing blood sugar is a key part of managing type 2 diabetes, a disease that affects over 250 million people worldwide.

Today in Major Studies...keeping you current

Receive free subspecialty "5-minute updates" via email

First-in-Human Study Demonstrating Pharmacological Activation of Heme Oxygenase-1 in Humans
Clinical Pharmacology & Therapeutics, 12/08/09

Amgen Presents Data From First Nplate Study in Children With Chronic ITP
Amgen, 12/08/09

Nplate Data From MDS Studies Presented at ASH
Amgen, 12/07/09

 See all of Major Studies

Today in Other Drugs...keeping you current

Receive free subspecialty "5-minute updates" via email

Pioglitazone and mechanisms of CV protection
QJM: An International Journal of Medicine, 12/08/09

Inflammatory breast cancer: what are the treatment options
Expert Opinion in Pharmacotherapy, 12/08/09

Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes
Expert Opinion on Investigational Drugs, 12/08/09

 See all of Other Drugs